New research presented in October at the 6th Neurodegenerative Conditions Research and Development Conference in San Francisco demonstrates the role of the investigational compound IRX4204 in alleviating cognitive decline in animal models of Alzheimer's disease (AD). The presentation entitled "Investigation of the RXR-specific agonist IRX4204 as a Disease Modifying Agent of Alzheimer's Disease Neuropathology and Cognitive Impairment" was made by lead researcher Giulio Maria Pasinetti, MD, PhD, of the Mount Sinai School of Medicine in New York City.
Read more at: http://medicalxpress.com/news/2012-10-drug-animal-alzheimer-parkinson-dementia.html#jCp
Read more at: http://medicalxpress.com/news/2012-10-drug-animal-alzheimer-parkinson-dementia.html#jCp
No comments:
Post a Comment